Correction: Histone acetyltransferase PCAF Up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling (Molecular Cancer, (2013), 12, 1, (96), 10.1186/1476-4598-12-96);Histone acetyltransferase PCAF Up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Zheng, Xin ^a   Gai, Xiaohong ^a   Ding, Feihu ^a   Lu, Zhongtang ^a   Tu, Kangsheng ^a   Yao, Yingmin ^a   Liu, Qingguang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

AKT signaling; Apoptosis; Hepatocellular carcinoma; Histone H4; PCAF

Indexed keywords

CASPASE 3; CASPASE 7; HISTONE ACETYLTRANSFERASE PCAF; HISTONE H4; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE OVEREXPRESSION; GROWTH DISORDER; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; UPREGULATION;

ACETYLATION; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HISTONES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; P300-CBP TRANSCRIPTION FACTORS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR BURDEN; UP-REGULATION;

EID: 84883104850     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-022-01637-2     Document Type: Erratum

References (34)

1. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005, 25:212-225. 10.1055/s-2005-871200, 15918149.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37(Suppl 8):S4-S66.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823. 10.7326/0003-4819-139-10-200311180-00009, 14623619.
4. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324. 10.1038/382319a0, 8684459.
5. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352. 10.1038/38664, 9311776.
6. Marcus GA, Silverman N, Berger SL, Horiuchi J, Guarente L. Functional similarity and physical association between GCN5 and ADA2: putative transcriptional adaptors. EMBO J 1994, 13:4807-4815. 395419, 7957049.
7. Tuo H, Zheng X, Tu K, Zhou Z, Yao Y, Liu Q. Expression of PCAF in hepatocellular carcinoma and its clincial significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013, 29:297-300.
8. MacDonald VE, Howe LJ. Histone acetylation: where to go and how to get there. Epigenetics 2009, 4:139-143. 10.4161/epi.4.3.8484, 19430203.
9. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001, 58:728-736. 10.1007/PL00000896, 11437234.
10. Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, Zheng ZQ. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochim Biophys Sin (Shanghai) 2012, 44:80-91.
11. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 2003, 983:220-231. 10.1111/j.1749-6632.2003.tb05977.x, 12724227.
12. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. Histone deacetylase inhibitor trichostatin a induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003, 103:572-576. 10.1002/ijc.10699, 12494463.
13. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'Anneo A, Di Leonardo E, Di Fazio P, Vento R, Tesoriere G. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 2008, 32:177-184.
14. Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterol 2006, 130:2130-2144.
15. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114:2926-2935. 10.1182/blood-2009-05-220889, 2756203, 19641186.
16. Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 2007, 13:1140-1148. 10.1158/1078-0432.CCR-06-1751, 17317822.
17. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868. 10.1016/S0092-8674(00)80595-4, 10102273.
18. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511. 10.1101/gad.12.22.3499, 317244, 9832503.
19. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
20. Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, Floyd RA, Roberts LR. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes, Chromosomes Cancer 2013, 52:225-236. 10.1002/gcc.22022, 23109092.
21. Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM, et al. The transcription factor GLI1 mediates TGFbeta1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One 2012, 7:e49581. 10.1371/journal.pone.0049581, 3501480, 23185371.
22. Zheng X, Yao Y, Xu Q, Tu K, Liu Q. Evaluation of glioma-associated oncogene 1 expression and its correlation with the expression of sonic hedgehog, E-cadherin and S100a4 in human hepatocellular carcinoma. Mol Med Rep 2010, 3:965-970.
23. Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M, Yamamoto M. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001, 18:1271-1278.
24. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002, 3:224-229. 10.1093/embo-reports/kvf053, 1084017, 11882541.
25. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005, 83:344-353. 10.1139/o05-041, 15959560.
26. Coradini D, Speranza A. Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 2005, 26:1025-1033. 10.1111/j.1745-7254.2005.00195.x, 16115366.
27. Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004, 10:4822-4830. 10.1158/1078-0432.CCR-04-0349, 15269158.
28. Schiltz RL, Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim Biophys Acta 2000, 1470:M37-M53.
29. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani Y. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J Biol Chem 1999, 274:1189-1192. 10.1074/jbc.274.3.1189, 9880483.
30. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38:756-768.
31. Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 2012, 11:2458-2466. 10.4161/cc.20864, 3404877, 22713239.
32. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004, 53:519-526. 10.1007/s00280-004-0767-4, 15004724.
33. Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, et al. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology 2011, 53:1226-1236. 10.1002/hep.24174, 21480327.
34. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C, Avantaggiati ML. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol 2010, 225:394-405. 10.1002/jcp.22285, 3614009, 20589832.